Mar 26th 2020

First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01

Mar 24th 2020

Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models

More news



Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.



Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in attractive markets.



Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €2m up to €20m over the life of the investment.



Managing and investing out of funds WP III and WP IV.

More than €400m of funds raised dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.